The humanized monoclonal antibody Herceptin® (trastuzumab; Genentech Inc., San Francisco, CA), which binds to the extracellular domain of HER2, is the standard of care for breast cancers with HER2 amplification. Here, ERBB2 is linked to breast cancer.